Monthly High-Dose Vitamin D Treatment for the Prevention of Functional Decline: A Randomized Clinical Trial
Heike A. Bischoff-Ferrari,Bess Dawson-Hughes,E. John Orav,Hannes B. Staehelin,Otto W. Meyer,Robert Theiler,Walter Dick,Walter C. Willett,Andreas Egli +8 more
Reads0
Chats0
TLDR
Although higher monthly doses of vitamin D were effective in reaching a threshold of at least 30 ng/mL of 25-hydroxyvitamin D, they had no benefit on lower extremity function and were associated with increased risk of falls compared with 24,000 IU.Abstract:
Importance Vitamin D deficiency has been associated with poor physical performance. Objective To determine the effectiveness of high-dose vitamin D in lowering the risk of functional decline. Design, Setting, and Participants One-year, double-blind, randomized clinical trial conducted in Zurich, Switzerland. The screening phase was December 1, 2009, to May 31, 2010, and the last study visit was in May 2011. The dates of our analysis were June 15, 2012, to October 10, 2015. Participants were 200 community-dwelling men and women 70 years and older with a prior fall. Interventions Three study groups with monthly treatments, including a low-dose control group receiving 24 000 IU of vitamin D 3 (24 000 IU group), a group receiving 60 000 IU of vitamin D 3 (60 000 IU group), and a group receiving 24 000 IU of vitamin D 3 plus 300 μg of calcifediol (24 000 IU plus calcifediol group). Main Outcomes and Measures The primary end point was improving lower extremity function (on the Short Physical Performance Battery) and achieving 25-hydroxyvitamin D levels of at least 30 ng/mL at 6 and 12 months. A secondary end point was monthly reported falls. Analyses were adjusted for age, sex, and body mass index. Results The study cohort comprised 200 participants (men and women ≥70 years with a prior fall). Their mean age was 78 years, 67.0% (134 of 200) were female, and 58.0% (116 of 200) were vitamin D deficient ( P = .001), they were not more effective in improving lower extremity function, which did not differ among the treatment groups ( P = .26). However, over the 12-month follow-up, the incidence of falls differed significantly among the treatment groups, with higher incidences in the 60 000 IU group (66.9%; 95% CI, 54.4% to 77.5%) and the 24 000 IU plus calcifediol group (66.1%; 95% CI, 53.5%-76.8%) group compared with the 24 000 IU group (47.9%; 95% CI, 35.8%-60.3%) ( P = .048). Consistent with the incidence of falls, the mean number of falls differed marginally by treatment group. The 60 000 IU group (mean, 1.47) and the 24 000 IU plus calcifediol group (mean, 1.24) had higher mean numbers of falls compared with the 24 000 IU group (mean, 0.94) ( P = .09). Conclusions and Relevance Although higher monthly doses of vitamin D were effective in reaching a threshold of at least 30 ng/mL of 25-hydroxyvitamin D, they had no benefit on lower extremity function and were associated with increased risk of falls compared with 24 000 IU. Trial Registration clinicaltrials.gov Identifier:NCT01017354read more
Citations
More filters
Journal ArticleDOI
American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis — 2016
Pauline M. Camacho,Steven M. Petak,Neil Binkley,Dima L. Diab,Leslie S. Eldeiry,Azeez Farooki,Steven T. Harris,Daniel L. Hurley,Jennifer J. Kelly,E. Michael Lewiecki,Rachel Pessah-Pollack,Michael R. McClung,Sunil J. Wimalawansa,Nelson B. Watts +13 more
TL;DR: A large number of the patients in this study had atypical femur fracture and the results confirmed the need for further investigation into the mechanisms leading to and effects of these fractures.
Journal ArticleDOI
UK clinical guideline for the prevention and treatment of osteoporosis
Juliet E. Compston,A Cooper,Cyrus Cooper,Neil Gittoes,Celia L Gregson,Nicholas C. Harvey,S Hope,John A. Kanis,Eugene V. McCloskey,Kenneth E. S. Poole,David M. Reid,Peter Selby,F. Thompson,Anne Thurston,N Vine +14 more
TL;DR: The guideline, which has received accreditation from the National Institute of Health and Care Excellence (NICE), provides a comprehensive overview of the assessment and management of osteoporosis for all healthcare professionals who are involved in its management.
Journal ArticleDOI
Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions.
Roger Bouillon,Claudio Marcocci,Geert Carmeliet,Daniel D. Bikle,John H. White,Bess Dawson-Hughes,Paul Lips,Craig F Munns,Craig F Munns,Marise Lazaretti-Castro,Andrea Giustina,John P. Bilezikian +11 more
TL;DR: There is a need for continued ongoing and future basic and clinical studies to better define whether vitamin D status can be optimized to improve many aspects of human health, and what is plausible regarding the health effects of vitamin D.
Journal ArticleDOI
Vitamin D: Nutrient, Hormone, and Immunomodulator
TL;DR: Experimental data and clinical observations confirm that vitamin D and VDR signaling together have a suppressive role on autoimmunity and an anti-inflammatory effect, promoting dendritic cell and regulatory T-cell differentiation and reducing T helper Th 17 cell response and inflammatory cytokines secretion.
Journal ArticleDOI
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.
Richard Eastell,Clifford J. Rosen,Dennis M. Black,Angela M. Cheung,M. Hassan Murad,Dolores M. Shoback,Dolores M. Shoback +6 more
TL;DR: Evidence from clinical trials and insights from clinical experience with pharmacologic therapies for osteoporosis were critically evaluated in formulating this guideline for the management of postmenopausal osteoporeosis.
References
More filters
Journal ArticleDOI
A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation☆
TL;DR: The method of classifying comorbidity provides a simple, readily applicable and valid method of estimating risk of death fromComorbid disease for use in longitudinal studies and further work in larger populations is still required to refine the approach.
Journal ArticleDOI
Frailty in Older Adults Evidence for a Phenotype
Linda P. Fried,Catherine M. Tangen,Jeremy D. Walston,Anne B. Newman,Calvin H. Hirsch,John S. Gottdiener,Teresa E. Seeman,Russell P. Tracy,Willem J. Kop,B Gregory Burke,Mary Ann McBurnie +10 more
TL;DR: This study provides a potential standardized definition for frailty in community-dwelling older adults and offers concurrent and predictive validity for the definition, and finds that there is an intermediate stage identifying those at high risk of frailty.
Journal Article
Cardiovascular Health Study Collaborative Research Group : Frailty in older adults : evidence for a phenotype
Journal ArticleDOI
A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission.
Jack M. Guralnik,Eleanor M. Simonsick,Luigi Ferrucci,Robert J. Glynn,Lisa F. Berkman,Dan G. Blazer,Paul A. Scherr,Robert B. Wallace +7 more
TL;DR: Evidence is presented that performance measures can validly characterize older persons across a broad spectrum of lower extremity function and that performance and self-report measures may complement each other in providing useful information about functional status.
Journal ArticleDOI
Epidemiology of Sarcopenia among the Elderly in New Mexico
Richard N. Baumgartner,Kathleen M. Koehler,Dympna Gallagher,Linda J. Romero,Steven B. Heymsfield,Robert Ross,Philip J. Garry,Robert D. Lindeman +7 more
TL;DR: Some of the first estimates of the extent of the public health problem posed by sarcopenia are provided, independent of ethnicity, age, morbidity, obesity, income, and health behaviors.